What is the current stock price of Cosmos Health Inc. (COSM)?

As of the latest market data, Cosmos Health Inc. (COSM) is trading at $0.27. The stock has seen a gain of 0.95% today.

Does Cosmos Health Inc. (COSM) pay a dividend?

Based on current data, Cosmos Health Inc. does not have a confirmed active dividend policy.

What is the market cap of Cosmos Health Inc.?

The current market capitalization of Cosmos Health Inc. (COSM) is approximately unavailable.

Cosmos Health Inc. (COSM) Stock Price, News & Key Metrics

globenewswire.com

1d ago

Cosmos Health Releases 2026–2029 Guidance: Targeting $200M Revenue, $71M Gross Profit, and $44M Adjusted EBITDA by 2029 — Building an Innovative, High-Margin Healthcare Platform with Strong Cash Generation

Revenue increasing 207% at a 32% CAGR: From $65.3 million in 2025 to $200.6 million by 2029, driven by strong growth across all core segments Gross profit growing 801% to $71.2M: Margins expanding from 12.1% to 35.5% — driven by a structural shift toward high-margin proprietary segments Net income improving by $50.1M: Transition to profitability in 2027; net income of $31.0 million by 2029 Self-funding growth model: Operating cash flow turning positive in 2027 at $11.9 million, more than doubling to $24.0 million by 2029 Balance sheet transformation: Cash up 18-fold to $62.9 million; all convertible notes repaid; cash anticipated to exceed total debt levels by 2027 Shareholder value: stockholders' equity up 402% to $92.3 million and per-share value creation with EPS of $0.73 by 2029 Clear growth drivers: High-margin proprietary products, expansion of the distribution and manufacturing platform, global partnerships, advancement of the R&D pipeline, AI-driven efficiencies, and disciplined capital allocation — with the U.S. serving as a new growth engine alongside selective M&A activity CHICAGO, May 26, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced its financial guidance for the 2026–2029 period. Cosmos Health enters this guidance period following its strongest financial performance in Company history — full year 2025 revenue of $65.3 million, up 20% year-over-year, with gross profit increasing 83%, gross margin expanding 418 basis points, and cash rising more than tenfold to $3.5 million.

COSM

Cosmos Health Releases 2026–2029 Guidance: Targeting $200M Revenue, $71M Gross Profit, and $44M Adjusted EBITDA by 2029 — Building an Innovative, High-Margin Healthcare Platform with Strong Cash Generation

Cosmos Health Announces Expiration of 4,874,126 Series B Warrants Unexercised; ~38% of Total Outstanding Warrants

Cosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders' Equity Up 7.6%; Cash of $2.2M; Record Momentum Continues into Q2 with U.S. Expansion Underway

Cosmos Health, through its Subsidiary Cana Laboratories, Enters into an Advisory Agreement with the European Investment Bank (EIB) for the Financing of its €50M R&D Program; EIB Financing Represents up to 50%, or €25M, under the EIB's Venture Debt Program

Cosmos Health Announces Withdrawal of Registration Statement on Form S-1

Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months

Cosmos Health Releases 2026–2029 Guidance: Targeting $200M Revenue, $71M Gross Profit, and $44M Adjusted EBITDA by 2029 — Building an Innovative, High-Margin Healthcare Platform with Strong Cash Generation

Cosmos Health Announces Expiration of 4,874,126 Series B Warrants Unexercised; ~38% of Total Outstanding Warrants

Cosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders' Equity Up 7.6%; Cash of $2.2M; Record Momentum Continues into Q2 with U.S. Expansion Underway

Cosmos Health, through its Subsidiary Cana Laboratories, Enters into an Advisory Agreement with the European Investment Bank (EIB) for the Financing of its €50M R&D Program; EIB Financing Represents up to 50%, or €25M, under the EIB's Venture Debt Program

Cosmos Health Announces Withdrawal of Registration Statement on Form S-1

Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months